A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality

Intensive Care Medicine

Volumn 41, Issue 9, 2015, Pages 1601-1610

  Bassetti, Matteo ^a   Righi, Elda ^a   Ansaldi, Filippo ^b   Merelli, Maria ^a   Scarparo, Claudio ^a   Antonelli, Massimo ^c   Garnacho Montero, Jose ^d   Diaz Martin, Ana ^d   Palacios Garcia, Inmaculada ^d   Luzzati, Roberto ^e   Rosin, Chiara ^e   Lagunes, Leonel ^f   Rello, Jordi ^f   Almirante, Benito ^f   Scotton, Pier Giorgio ^g   Baldin, Gianmaria ^g   Dimopoulos, George ^h   Nucci, Marcio ⁱ   Munoz, Patricia ^j   Vena, Antonio ^j   Bouza, Emilio ^j   de Egea, Viviana ^j   Colombo, Arnaldo Lopes ^k   Tascini, Carlo ^l   Menichetti, Francesco ^l   Tagliaferri, Enrico ^l   Brugnaro, Pierluigi ^m   Sanguinetti, Maurizio ^c   Mesini, Alessio ^b   Sganga, Gabriele ^c   Viscoli, Claudio ^b   Tumbarello, Mario ^c   more..

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g Treviso Hospital   (Italy)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m Venezia Hospital   (Italy)

more..

Author keywords

Abdominal candidiasis; Adequate treatment; Antifungal therapy; Candida; Mortality; Source control

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; ANTIMICROBIAL THERAPY; APACHE; ARTICLE; BACTERIAL INFECTION; BRAZIL; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDIASIS; CLINICAL STUDY; COHORT ANALYSIS; CONCURRENT INFECTION; FEMALE; FUNGUS ISOLATION; GREECE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTRA ABDOMINAL CANDIDIASIS; ITALY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERITONITIS; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SEPTIC SHOCK; ABDOMEN; CLINICAL TRIAL; COMPLICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; RISK ASSESSMENT; RISK FACTOR; SPAIN;

ABDOMEN; BRAZIL; CANDIDIASIS; COHORT STUDIES; FEMALE; GREECE; HUMANS; ITALY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SHOCK, SEPTIC; SPAIN;

EID: 84940453236     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-015-3866-2     Document Type: Article

References (30)

1. Rebolledo M, Sarria JC (2013) Intra-abdominal fungal infections. Curr Opin Infect Dis 26(5):441–446
2. Blot SI, Vandewoude KH, De Waele JJ (2007) Candida peritonitis. Curr Opin Crit Care 13:195–199
3. Carneiro HA, Mavrakis A, Mylonakis E (2011) Candida peritonitis: an update on the latest research and treatments. World J Surg 35:2650–2659
4. Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, Mantz J, Desmonts JM (2002) Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 137:1341–1346
5. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, Hennequin C, Martin C (2006) Candida as a risk factor for mortality in peritonitis. Crit Care Med 34:646–652
6. Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group, the Norwegian Yeast Study Group (2002) Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 30:541–547
7. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P et al (2013) A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 39:2092–2106
8. de Ruiter J, Weel J, Manusama E, Kingma WP, van der Voort PH (2009) The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 37(6):522–527
9. Lee SC, Fung CP, Chen HY, Li CT, Jwo SC, Hung YB, See LC, Liao HC, Loke SS, Wang FL, Lee JC (2002) Candida peritonitis due to peptic ulcer perforation: incidence rate, risk factors, prognosis and susceptibility to fluconazole and amphotericin B. Diagn Microbiol Infect Dis 44(1):23–27
10. Montravers P, Mira JP, Gangneux JP, Leroy O, Lortholary O, AmarCand study group (2011) A multicentre study of antifungal strategies and outcome of Candida spp. peritonitis in intensive-care units. Clin Microbiol Infect 17:1061–1067
11. Shields RK, Nguyen MH, Press EG, Clancy CJ (2014) Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58(12):7601–7605
12. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L et al (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503–535
13. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microb Infect 18(Suppl 7):19–37
14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
15. Montravers P, Dupont H, Eggimann P (2013) Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis. Intensive Care Med 39:2226–2230
16. Messer SA, Moet GJ, Kirvy JT, Jones RN (2009) Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006–2007). J Clin Microbiol 47:1942–1946
17. Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, Parra A, Trecarichi EM, Sanguinetti M, Posteraro B et al (2013) Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51(12):4167–4172
18. Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40:1241–1255
19. Delaloye J, Calandra T (2014) Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5:161–169
20. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, Diaz-Martin A, Luzzati R, Rosin C, Lagunes L et al (2014) A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 40:839–845
21. Guzman JA, Tchokonte R, Sobel JD (2011) Septic shock due to candidemia: outcomes and predictors of shock development. J Clin Med Res 3:65–71
22. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739–1746
23. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645
24. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, Fontanet A, Bretagne S, Dromer F (2014) French Mycosis Study Group: worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40:1303–1312
25. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43:25–31
26. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N (2009) The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Terapeutics 16:508–511
27. Shan YS, Sy ED, Wang ST, Lee JC, Lin PW (2006) Early presumptive therapy with fluconazole for occult Candida infection after gastrointestinal surgery. World J Surg 30(1):119–126
28. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, Clark NM (2012) Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother 67:707–714
29. Kludze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW (2010) The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol 48:436–439
30. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G et al (2007) Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 45:1843–1850